Teva will continue to offer a comprehensive portfolio of both standard and complex generics, as well as biosimilars, as it seeks to defend its position as the world’s leading generics supplier, according to Kåre Schultz, who took charge as the Israeli group’s chief executive officer in November last year.
“We want to maintain our leadership in generics,” Schultz told investors. “We want to be both in simple generics, complex...






